Positioning Therapy for Ulcerative Colitis

Ari Grinspan, Asher Kornbluth

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Ulcerative colitis (UC) is a chronic inflammatory condition of the colon, characterized by diffuse mucosal inflammation, bloody diarrhea, and urgency. The mainstay of treatment has been mesalamine agents, steroids, thiopurines, and anti-tumor necrosis factor alpha (TNF-α) antibodies. Over the past several years, new therapies have emerged which have provided clinicians new treatment options as well as new challenges in deciding which treatment is best for their patient at given points in their disease course. These agents include budesonide-Multi-Matrix System (MMX), adalimumab, golimumab, and vedolizumab. In addition, randomized controlled trials have investigated a combination therapy of infliximab and azathioprine and a controlled trial of infliximab versus cyclosporine for intravenous steroid refractory UC. This review will focus on where these agents may be optimally positioned in treatment algorithms for UC.

Original languageEnglish
Article number29
JournalCurrent Gastroenterology Reports
Issue number8
StatePublished - 6 Aug 2015


  • Anti-TNF-α antibody
  • Budesonide
  • Combination therapy
  • Cyclosporine
  • Ulcerative colitis
  • Vedolizumab


Dive into the research topics of 'Positioning Therapy for Ulcerative Colitis'. Together they form a unique fingerprint.

Cite this